Godavari Biorefineries Clinches European Patent for Anticancer Breakthrough, Validated in Spain & UK

Godavari Biorefineries Ltd has achieved a major milestone in its biotech journey by securing a European patent for its novel anticancer molecule, now officially validated in Spain, the United Kingdom, and under the Unitary Patent system. The patented compound, part of the company’s Anti-Cancer Research Segment, has demonstrated proven efficacy against both cancer cells and cancer stem cells, a critical frontier in oncology.

 

This development significantly strengthens Godavari’s global innovation footprint and opens doors for licensing opportunities and strategic partnerships in the pharmaceutical space. The announcement triggered a sharp rally in the stock, which hit the 5% upper circuit on July 4, closing at ₹256.75.

 

The company’s CMD, Samir Somaiya, emphasized that this patent reinforces their commitment to sustainable, high-value biotech solutions. Godavari is also progressing on its 200 KLPD grain-based distillery, expected to be commissioned in Q4 FY26, and is exploring multi-feedstock flexibility to boost operational resilience.

 

 Key Highlights:

 

Source: CNBC TV18 – Godavari Biorefineries Secures European Patent | Business Standard